Palvella Therapeutics (PVLA) Cash & Equivalents (2016 - 2024)
Historic Cash & Equivalents for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to $14.2 million.
- Palvella Therapeutics' Cash & Equivalents fell 6828.79% to $14.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $14.2 million, marking a year-over-year decrease of 6828.79%. This contributed to the annual value of $7.4 million for FY2023, which is 8097.58% down from last year.
- According to the latest figures from Q3 2024, Palvella Therapeutics' Cash & Equivalents is $14.2 million, which was down 6828.79% from $14.5 million recorded in Q2 2024.
- Palvella Therapeutics' 5-year Cash & Equivalents high stood at $125.1 million for Q3 2021, and its period low was $6.2 million during Q1 2024.
- Moreover, its 5-year median value for Cash & Equivalents was $54.3 million (2022), whereas its average is $57.6 million.
- Per our database at Business Quant, Palvella Therapeutics' Cash & Equivalents skyrocketed by 16882.98% in 2021 and then plummeted by 8709.09% in 2024.
- Quarter analysis of 5 years shows Palvella Therapeutics' Cash & Equivalents stood at $70.4 million in 2020, then soared by 67.19% to $117.8 million in 2021, then plummeted by 67.19% to $38.6 million in 2022, then crashed by 80.98% to $7.4 million in 2023, then surged by 93.29% to $14.2 million in 2024.
- Its Cash & Equivalents was $14.2 million in Q3 2024, compared to $14.5 million in Q2 2024 and $6.2 million in Q1 2024.